210 related articles for article (PubMed ID: 32318342)
1. Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
Ferrari L; Carugno M; Mensi C; Pesatori AC
Front Oncol; 2020; 10():445. PubMed ID: 32318342
[TBL] [Abstract][Full Text] [Related]
2. The Use of Immunohistochemistry, Fluorescence
Rozitis E; Johnson B; Cheng YY; Lee K
Front Oncol; 2020; 10():1742. PubMed ID: 33014860
[TBL] [Abstract][Full Text] [Related]
3. A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.
Duong BTV; Wu L; Green BJ; Bavaghar-Zaeimi F; Wang Z; Labib M; Zhou Y; Cantu FJP; Jeganathan T; Popescu S; Pantea J; de Perrot M; Kelley SO
EBioMedicine; 2020 Nov; 61():103031. PubMed ID: 33045471
[TBL] [Abstract][Full Text] [Related]
4. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.
Cavallari I; Urso L; Sharova E; Pasello G; Ciminale V
Front Oncol; 2019; 9():740. PubMed ID: 31475103
[TBL] [Abstract][Full Text] [Related]
5. Circulating biomarkers in malignant pleural mesothelioma.
Viscardi G; Di Natale D; Fasano M; Brambilla M; Lobefaro R; De Toma A; Galli G
Explor Target Antitumor Ther; 2020; 1(6):434-451. PubMed ID: 36046389
[TBL] [Abstract][Full Text] [Related]
6. Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
Bruno R; Alì G; Fontanini G
J Thorac Dis; 2018 Jan; 10(Suppl 2):S342-S352. PubMed ID: 29507804
[TBL] [Abstract][Full Text] [Related]
7. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
Kim K; Ko Y; Oh H; Ha M; Kang J; Kwon EJ; Kang JW; Kim Y; Heo HJ; Kim G; Kim JW; Kim YH
J Toxicol Environ Health A; 2020 Feb; 83(3):126-134. PubMed ID: 32114955
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review.
Lo Russo G; Tessari A; Capece M; Galli G; de Braud F; Garassino MC; Palmieri D
Front Oncol; 2018; 8():650. PubMed ID: 30622932
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs dysregulation in human malignant pleural mesothelioma.
Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
[TBL] [Abstract][Full Text] [Related]
11. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
12. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
13. Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.
Birnie KA; Prêle CM; Thompson PJ; Badrian B; Mutsaers SE
Oncotarget; 2017 Sep; 8(44):78193-78207. PubMed ID: 29100460
[TBL] [Abstract][Full Text] [Related]
14. [Malignant pleural mesothelioma: diagnosis and treatment].
Delourme J; Dhalluin X; Cortot AB; Lafitte JJ; Scherpereel A
Rev Pneumol Clin; 2013 Feb; 69(1):26-35. PubMed ID: 23333048
[TBL] [Abstract][Full Text] [Related]
15. DNA Methylation of
Cugliari G; Catalano C; Guarrera S; Allione A; Casalone E; Russo A; Grosso F; Ferrante D; Viberti C; Aspesi A; Sculco M; Pirazzini C; Libener R; Mirabelli D; Magnani C; Dianzani I; Matullo G
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233407
[TBL] [Abstract][Full Text] [Related]
16. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
[TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Zhang W; Wu X; Wu L; Zhang W; Zhao X
Ann Transl Med; 2015 Aug; 3(13):182. PubMed ID: 26366399
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and prognosis-review of biomarkers for mesothelioma.
Sun HH; Vaynblat A; Pass HI
Ann Transl Med; 2017 Jun; 5(11):244. PubMed ID: 28706912
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors-Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment.
Yoshikawa Y; Kuribayashi K; Minami T; Ohmuraya M; Kijima T
Front Oncol; 2020; 10():554570. PubMed ID: 33381446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
